P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX.

• A. Rawstron,
• N. Webster,
• A. Pitchford,
• S. Dalal,
• A. Bloor,
• R. de Tute,
• A. Hockaday,
• S. Jackson,
• D. Cairns,
• N. Greatorex,
• D. Allsup,
• T. Munir,
• P. Hillmen

Affiliations

A. Rawstron

1 HMDS, Leeds Cancer Centre

N. Webster

2 Experimental Haematology, University of Leeds

A. Pitchford

3 Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds

S. Dalal

2 Experimental Haematology, University of Leeds

A. Bloor

4 Haematology, The Christie NHS Foundation Trust, Manchester

R. de Tute

1 HMDS, Leeds Cancer Centre

A. Hockaday

3 Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds

S. Jackson

3 Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds

D. Cairns

3 Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds

N. Greatorex

3 Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds

D. Allsup

5 Haematology, Hull York Medical School, Hull

T. Munir

6 Haematology, Leeds Cancer Centre, Leeds, United Kingdom

P. Hillmen

2 Experimental Haematology, University of Leeds